<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814801</url>
  </required_header>
  <id_info>
    <org_study_id>CR010297</org_study_id>
    <secondary_id>GAL-JPN-5</secondary_id>
    <nct_id>NCT00814801</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease</brief_title>
  <official_title>Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Pharmaceutical K.K.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Pharmaceutical K.K.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day
      and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment
      of patients with Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), double-blind (neither the physician nor
      the patient know the name of the study medication), placebo-controlled, parallel-group study
      to evaluate the efficacy and safety of two fixed doses of galantamine (16 and 24 milligrams
      per day [mg/day]) in patients with Alzheimer's disease. The study consists of a 4-week
      screening period during which all patients will receive placebo, and a 24-week double-blind
      treatment period during which patients will receive placebo, galantamine 16 mg/day, or
      galantamine 24 mg/day. For patients receiving galantamine treatment, the starting dose is 8
      mg/day and increases at 4-week intervals in increments of 8 mg/day. The primary measures of
      effectiveness are the change from baseline to the end of the study (week 24) in the
      Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) and the
      Clinician's Interview-Based Impression of Change plus - Japan (CIBIC plus-J). Safety
      assessments include the incidence of adverse events, clinical laboratory tests, vital signs,
      electrocardiograms (ECGs), and physical examination findings. The study hypothesis is that
      galantamine will be effective in the treatment of Alzheimer's disease. Study drug taken
      orally twice a day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>ADAS-J cog is the Japanese version of the cognitive function subscale of the Alzheimer's disease assessment scale (ADAS). This scale is used to detect changes in cognitive function in individuals with Alzheimer disease on the basis of three domains: memory, language and behavior. The minimum score is zero (0) and means well cognitive function. The maximum total score is 70 points, and the larger the score, the more severe the degree of impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</measure>
    <time_frame>24 weeks</time_frame>
    <description>CIBIC plus-J is the Japanese version of the Clinician's Interview-based Impression of Change plus the caregiver's input (CIBIC plus). It is a seven-point categorical assessment scale for evaluating the efficacy of antidementia drugs, ranging from &quot;markedly improved&quot; to &quot;markedly worse&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Disability Assessment for Dementia (DAD)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Each of the 40 item of the DAD is scored as 1 point= Yes, 0 point= No, or non applicable= N/A. A total score (minimum=0; maximum=40) is the sum of points for each questions converted out 100. Items rated as Not Applicable (N/A) are not considered for the total score. The final score is a percentage that gives an appreciation of global function in activity of daily life (ADL). Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Behave-AD is a CIBIC plus-J subscale that rates the patient's severity of psychotic symptoms. This four-point scale varies from 0 (=none) to 3 (= serious).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mental Function Impairment Scale (MENFIS)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>MENFIS is a Clinician's Interview-Based Impression of Change (CIBIC) plus-Japan subscale that rates the patient's severity for mental function impairment. This seven-point scale varies from 0 (= absolutely no impairment) to 6 (=complete impairment).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine 16 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Galantamine 24 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine 16 mg/day</intervention_name>
    <description>Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.</description>
    <arm_group_label>Galantamine 16 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine 24 mg/day</intervention_name>
    <description>Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.</description>
    <arm_group_label>Galantamine 24 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with a diagnosis of Alzheimer's disease according to the National
             Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and
             Related Disorders Association (NINCDS-ADRDA) criteria

          -  Having a Mini-Mental Status Examination (MMSE) score of 10 - 22 inclusive

          -  Having an Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog)
             score of at least 18

          -  Exhibiting an onset and progression of cognitive dysfunction during at least 6 months
             prior to the screening period

        Exclusion Criteria:

          -  Patients with neurodegenerative diseases other than Alzheimer's disease, such as Lewy
             bodies disease, (dementia due to tiny round structures made of proteins that develop
             within nerve cells in the brain), Parkinsonism, etc

          -  Patients with cognitive dysfunction due to cerebral damage resulting from a lack of
             oxygen, a brain injury, etc

          -  Patients with multi-infarct dementia (brought on by a series of strokes) or active
             cerebrovascular disease

          -  Patients with clinically significant cardiovascular disease

          -  Patients currently taking drugs such as a cholinesterase inhibitors, which improve
             cerebral circulation/metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Pharmaceutical K.K. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Pharmaceutical K.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=411&amp;filename=CR010297_CSR.pdf</url>
    <description>An Efficacy and Safety Study of Galantamine for the Treatment of Patients with Alzheimer's Disease.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <results_first_submitted>March 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2012</results_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognitive dysfunction</keyword>
  <keyword>Dementia</keyword>
  <keyword>Galantamine</keyword>
  <keyword>R113675</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Group</title>
        </group>
        <group group_id="P2">
          <title>Galantamine Group 1</title>
          <description>Galantamine 16 mg/day</description>
        </group>
        <group group_id="P3">
          <title>Galantamine Group 2</title>
          <description>Galantamine 24 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate as a subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change of patients for CIBIC plus-J</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing or change of caregiver</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
        </group>
        <group group_id="B2">
          <title>Galantamine Group 1</title>
          <description>Galantamine 16 mg/day</description>
        </group>
        <group group_id="B3">
          <title>Galantamine Group 2</title>
          <description>Galantamine 24 mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="191"/>
            <count group_id="B3" value="192"/>
            <count group_id="B4" value="574"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Six participants were excluded from the randomized patients as no evaluation on both ADAS and CIBIC was made after treatment with study medication.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.5" spread="7.6"/>
                    <measurement group_id="B2" value="75.6" spread="8.4"/>
                    <measurement group_id="B3" value="74.6" spread="8.8"/>
                    <measurement group_id="B4" value="75.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Six participants were excluded from the randomized patients as no evaluation on both Alzheimer's disease assessment scale (ADAS) and Clinician's Interview-Based Impression of Change (CIBIC) was made after treatment with study medication.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</title>
        <description>ADAS-J cog is the Japanese version of the cognitive function subscale of the Alzheimer's disease assessment scale (ADAS). This scale is used to detect changes in cognitive function in individuals with Alzheimer disease on the basis of three domains: memory, language and behavior. The minimum score is zero (0) and means well cognitive function. The maximum total score is 70 points, and the larger the score, the more severe the degree of impairment.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
          </group>
          <group group_id="O2">
            <title>Galantamine Group 1</title>
            <description>Galantamine 16 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Galantamine Group 2</title>
            <description>Galantamine 24 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)</title>
          <description>ADAS-J cog is the Japanese version of the cognitive function subscale of the Alzheimer's disease assessment scale (ADAS). This scale is used to detect changes in cognitive function in individuals with Alzheimer disease on the basis of three domains: memory, language and behavior. The minimum score is zero (0) and means well cognitive function. The maximum total score is 70 points, and the larger the score, the more severe the degree of impairment.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="5.89"/>
                    <measurement group_id="O2" value="-0.58" spread="5.87"/>
                    <measurement group_id="O3" value="-1.66" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.64</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.74</ci_lower_limit>
            <ci_upper_limit>-1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</title>
        <description>CIBIC plus-J is the Japanese version of the Clinician's Interview-based Impression of Change plus the caregiver's input (CIBIC plus). It is a seven-point categorical assessment scale for evaluating the efficacy of antidementia drugs, ranging from &quot;markedly improved” to “markedly worse”.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
          </group>
          <group group_id="O2">
            <title>Galantamine Group 1</title>
            <description>Galantamine 16 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Galantamine Group 2</title>
            <description>Galantamine 24 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)</title>
          <description>CIBIC plus-J is the Japanese version of the Clinician's Interview-based Impression of Change plus the caregiver's input (CIBIC plus). It is a seven-point categorical assessment scale for evaluating the efficacy of antidementia drugs, ranging from &quot;markedly improved” to “markedly worse”.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Markedly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Markedly worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Disability Assessment for Dementia (DAD)</title>
        <description>Each of the 40 item of the DAD is scored as 1 point= Yes, 0 point= No, or non applicable= N/A. A total score (minimum=0; maximum=40) is the sum of points for each questions converted out 100. Items rated as Not Applicable (N/A) are not considered for the total score. The final score is a percentage that gives an appreciation of global function in activity of daily life (ADL). Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
          </group>
          <group group_id="O2">
            <title>Galantamine Group 1</title>
            <description>Galantamine 16 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Galantamine Group 2</title>
            <description>Galantamine 24 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Disability Assessment for Dementia (DAD)</title>
          <description>Each of the 40 item of the DAD is scored as 1 point= Yes, 0 point= No, or non applicable= N/A. A total score (minimum=0; maximum=40) is the sum of points for each questions converted out 100. Items rated as Not Applicable (N/A) are not considered for the total score. The final score is a percentage that gives an appreciation of global function in activity of daily life (ADL). Higher scores represent less disability in ADL while lower scores indicate more dysfunction.</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="10.3"/>
                    <measurement group_id="O2" value="-1.0" spread="9.4"/>
                    <measurement group_id="O3" value="-2.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0774</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6207</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</title>
        <description>Behave-AD is a CIBIC plus-J subscale that rates the patient's severity of psychotic symptoms. This four-point scale varies from 0 (=none) to 3 (= serious).</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
          </group>
          <group group_id="O2">
            <title>Galantamine Group 1</title>
            <description>Galantamine 16 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Galantamine Group 2</title>
            <description>Galantamine 24 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)</title>
          <description>Behave-AD is a CIBIC plus-J subscale that rates the patient's severity of psychotic symptoms. This four-point scale varies from 0 (=none) to 3 (= serious).</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.1"/>
                    <measurement group_id="O2" value="-0.2" spread="4.2"/>
                    <measurement group_id="O3" value="-0.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8419</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7942</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mental Function Impairment Scale (MENFIS)</title>
        <description>MENFIS is a Clinician's Interview-Based Impression of Change (CIBIC) plus-Japan subscale that rates the patient's severity for mental function impairment. This seven-point scale varies from 0 (= absolutely no impairment) to 6 (=complete impairment).</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
          </group>
          <group group_id="O2">
            <title>Galantamine Group 1</title>
            <description>Galantamine 16 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Galantamine Group 2</title>
            <description>Galantamine 24 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mental Function Impairment Scale (MENFIS)</title>
          <description>MENFIS is a Clinician's Interview-Based Impression of Change (CIBIC) plus-Japan subscale that rates the patient's severity for mental function impairment. This seven-point scale varies from 0 (= absolutely no impairment) to 6 (=complete impairment).</description>
          <population>Intent-to-treat (ITT) population. Last observation carried forward (LOCF) end point.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.2"/>
                    <measurement group_id="O2" value="1.6" spread="5.2"/>
                    <measurement group_id="O3" value="1.9" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3141</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6089</p_value>
            <method>Least Square Means</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
        </group>
        <group group_id="E2">
          <title>Galantamine Group 1</title>
          <description>Galantamine 16 mg/day</description>
        </group>
        <group group_id="E3">
          <title>Galantamine Group 2</title>
          <description>Galantamine 24 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J V11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia folate deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Post-traumatic headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiration failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J V11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="194"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="194"/>
                <counts group_id="E2" events="44" subjects_affected="24" subjects_at_risk="192"/>
                <counts group_id="E3" events="61" subjects_affected="32" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E2" events="38" subjects_affected="26" subjects_at_risk="192"/>
                <counts group_id="E3" events="44" subjects_affected="21" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E2" events="43" subjects_affected="19" subjects_at_risk="192"/>
                <counts group_id="E3" events="31" subjects_affected="21" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="36" subjects_at_risk="194"/>
                <counts group_id="E2" events="53" subjects_affected="40" subjects_at_risk="192"/>
                <counts group_id="E3" events="51" subjects_affected="38" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="194"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="192"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="192"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="192"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="192"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="194"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results for a period as the sponsor requires.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director</name_or_title>
      <organization>Janssen Pharm KK Japan</organization>
      <phone>81-3-4411-5717</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

